Higher ANA Titers Linked to Increased Risks of Infertility and Miscarriage – Fertility Plus
Fertility Plus shared a post on LinkedIn:
“ANA in IVF
Recent research by Yoshihara et al. (2025) offers key insights into anti-nuclear antibodies (ANA) in reproductive health. They determined that low-titer ANA (≤1:160) does not significantly impact live birth rates, suggesting a threshold where these antibodies may become clinically relevant. Conversely, higher ANA titers have previously been linked to increased risks of infertility and miscarriage.
This study emphasizes the importance of monitoring ANA levels in pregnancy planning and highlights the need for further research into how these antibodies influence reproductive outcomes. Understanding these thresholds can empower couples during their fertility journeys.
Association between antinuclear antibodies and pregnancy prognosis in recurrent pregnancy loss patients Open Access
H Yoshihara, S Goto, Tamao Kitaori, M Sugiura-Ogasawara
Human Reproduction, Volume 40, Issue 2, February 2025, Pages 236–243.”
Stay updated on all scientific advances in the field of fertility with Fertility News.
-
Jun 19, 2026, 15:54Horace Roman: Sciatic Nerve Endometriosis – Prevent Muscle Atrophy Caused by Progressive Denervation
-
Jun 19, 2026, 15:36Why Does the Clock Read Older? – Fertility Plus
-
Jun 19, 2026, 15:28Asma Khalil: Study Raises Questions About Workplace Activities and Early Pregnancy Outcomes
-
Jun 19, 2026, 15:21Spindle Dynamics and Chromosome Segregation In Human Preimplantation Embryos – Fertility and Sterility
-
Jun 19, 2026, 15:12Today is World Sickle Cell Day – Preeclampsia Foundation
-
Jun 19, 2026, 14:59Marco Zaccaria: ESGE Webinar to Spotlight Advances in the Surgical Management of Parametrial Endometriosis
-
Jun 19, 2026, 14:46PMOS Does Not Make Conception Impossible – PCOS Awareness Association
-
Jun 19, 2026, 14:40Diana Kayal: Successful Fertility Programs Aren’t Built On Clinical Expertise Alone
-
Jun 19, 2026, 14:29Devyanshi Dixit: Call for Abstracts at GFWH 2026
